Last Update

2016-08-09T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong David Karpf?

Dr. David B. Karpf MD

Adj. Clinical Professor of Endocrinology

Stanford University

Direct Phone: (650) ***-****       

Email: d***@***.edu

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Stanford University School of Medicine

Stanford University

857 Serra Street, Suite 210

Stanford, California 94305

United States

Company Description

Stanford University, located between San Francisco and San Jose in the heart of California's Silicon Valley, is one of the world's leading teaching and research universities. Since its opening in 1891, Stanford has been dedicated to finding solutions to b ... more

Find other employees at this company (46,830)

Background Information

Employment History

Chief Medical Officer

Virobay Inc

Chief Medical Oficer and Vice President and Clinical Associate Professor

Metabolex , Inc.

Medical Director

Geron Corporation

Vice President of Clinical and Regulatory Affairs

Calydon , Inc.

Director of Clinical Research At Laboratories

Merck & Co. , Inc.

Faculty

University of California , San Francisco

Executive Director of Clinical Research

Hoffmann-La Roche Inc.

Education

Stanford University School of Medicine

UCSF School of Medicine

B.A.

Psychology and Biology

University of California , Berkeley

M.D.

M.D. degree

University of California , San Diego

MD

Johns Hopkins

MD

UC San Diego Medical School

degrees

Biology and Psychology

University of California , Berkeley

Web References (100 Total References)


ViroBay

www.virobayinc.com [cached]

David B. Karpf MD Chief Medical Officer

...
David B. Karpf MD Chief Medical Officer
David B. Karpf, M.D. has served as our Chief Medical Officer since October 2011. From December 2010 to October 2011, Dr. Karpf served as a life sciences consultant. From January 2004 to December 2010, Dr. Karpf served as Chief Medical Officer and Vice President of Clinical Affairs at Metabolex, Inc., now CymaBay Therapeutics, Inc., where he oversaw the development of clinical programs in various diseases, including type 2 diabetes, gout and dyslipdemia. From May 2001 to January 2004, Dr. Karpf served as Executive Director of Clinical Research and Regulatory Affairs at Geron Corporation, or Geron, a clinical stage biopharmaceutical company, where he oversaw early clinical programs in cancer and regenerative medicine. From May 2000 to May 2001, Dr. Karpf served as Vice President, Clinical and Regulatory Affairs at Calydon, Inc., a company that developed oncolytic virus cancer treatments, which was acquired by Cell Genesis, Inc. in September 2001. From October 1996 to May 2000, Dr. Karpf served as Executive Director of Clinical Research at Roche, where he was responsible for clinical development activities in endocrinology and metabolic bone disease. From August 1991 to December 1996, Dr. Karpf served as Director of Clinical Research at Merck Research Laboratories, where he played a pivotal role in the successful New Drug Application and launch of Fosamax™. Dr. Karpf has also held several academic positions and is currently an adjunct clinical professor of endocrinology at Stanford University School of Medicine. Dr. Karpf received a B.A. in Psychology and Biology from University of California, Berkeley and an M.D. from University of California, San Diego. He completed a residency in Internal Medicine and a fellowship in Endocrinology, Diabetes and Metabolism at University of California, Los Angeles School of Medicine and Cedars-Sinai Medical Center, and a post-doctoral fellowship in the Endocrine Unit at University of California, San Francisco School of Medicine.


Metabolex, Inc.

www.metabolex.com [cached]

David B. Karpf

...
David B. Karpf, M.D. Chief Medical Officer
Dr. Karpf joined Metabolex in 2004 as Chief Medical Officer and Vice President, Clinical and Regulatory Affairs. He previously was at Geron Corporation, where he served as executive medical director, clinical and regulatory affairs from 2001. Prior to Geron, Dr. Karpf was vice president, clinical and regulatory affairs at Calydon, Inc. and executive director of clinical research at Roche Global Development in Palo Alto. From 1991 to 1996, Dr. Karpf was director of clinical research at Merck Research Laboratories in Rahway, New Jersey. Dr. Karpf is currently a clinical professor with the Stanford University School of Medicine. He received his M.D. degree from University of California, San Diego.


"The number of people living in ...

m.mercurynews.com [cached]

"The number of people living in this valley with little-or-no access to health care is startling," observed Dr. David B. Karpf, clinical professor of endocrinology at the Stanford University School of Medicine.


"The number of people living in ...

m.mercurynews.com [cached]

"The number of people living in this valley with little-or-no access to health care is startling," observed Dr. David B. Karpf, clinical professor of endocrinology at the Stanford University School of Medicine.


Virobay Appoints David ...

www.biospace.com [cached]

Virobay Appoints David B. Karpf, M.D. as Chief Medicial Officer 11/3/2011 11:08:34 AM

MENLO PARK, Calif., Nov. 3, 2011 /PRNewswire/ --Virobay, Inc., a privately held biotechnology firm with a broad portfolio of cathepsin protease inhibitors for the treatment of autoimmune diseases, neuropathic pain, liver diseases and cancer, today announced the appointment of David B. Karpf, M.D. as chief medical officer. Dr. Karpf has more than 20 years of experience in guiding the clinical development of novel therapeutics, both at growing biotechnology firms and within large pharmaceutical companies, including all phases of development and spanning multiple therapeutic areas. Dr. Karpf will be responsible for all clinical, regulatory and medical affairs functions related to advancing Virobay's growing pipeline of novel product candidates.
"David joins Virobay at an exciting time," said Robert Booth, Ph.D., Virobay president and chief executive officer.
...
"Virobay possesses excellent science and high quality research and development assets, combined with a culture of innovation and commitment to advancing differentiated therapies that represent major steps forward in treating serious chronic diseases," said Dr. Karpf. "Cathepsins and calpain are exciting and important new target classes that could yield novel therapies for a number of different important disease indications. I believe that Virobay has the potential to lead this industry effort, and am pleased to join this promising company."
Dr. Karpf brings to Virobay extensive experience in clinical product development, including successful interactions with the FDA and international regulatory agencies. Dr. Karpf joins Virobay from Metabolex, where he served as chief medical officer and vice president, clinical affairs. While at Metabolex, Dr. Karpf oversaw the development of four clinical programs spanning type 2 diabetes, dyslipidemia, and gout, including 2 INDs, 7 Phase 1 trials and 6 Phase 2 trials. Prior to Metabolex, Dr. Karpf was executive director of clinical research and regulatory affairs at Geron where he provided oversight for Geron's early clinical programs in cancer and regenerative medicine. Prior to Geron, Dr. Karpf was vice president, clinical and regulatory affairs at Calydon, Inc. Prior to his tenure at Calydon, Dr. Karpf was executive director of clinical research at Roche Global Development in Palo Alto and was responsible for clinical development activities in metabolic bone disease and endocrinology, including managing the Phase 3 pivotal program for Boniva. Dr. Karpf was previously director of clinical research at Merck Research Laboratories in Rahway, New Jersey. During his time at Merck he designed, monitored, and completed Phase 2, 3 and 4 clinical trials on Fosamax and played a pivotal role in the successful NDA and launch of this product. In addition to his industry experience, Dr. Karpf has held several academic positions and is currently an adjunct clinical professor of endocrinology with the Stanford University School of Medicine, where he directs one of the endocrine subspecialty clinics. He received his M.D. degree from University of California, San Diego, served on the fulltime endocrine faculty at UCSF School of Medicine, and has published numerous scientific papers and abstracts in the fields of endocrinology, bone disease, dyslipidemia and cancer.

Similar Profiles

Other People with this Name

Other people with the name Karpf

Zac Karpf
Platte Valley National Bank

Brian Karpf
Young Berman Karpf & Gonzalez P.A

Paul Karpf
Hawthorne Cat

Benjamin Karpf
Bouhan Williams and Levy LLP

Steven Karpf
Dermody Properties

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory